No abstract

Elective Percutaneous Coronary Intervention after Fibrinolysis: REMAT Data (Madre Teresa Registry)Background: Acute myocardial infarction (AMI) has a high morbidity and mortality and represents a public health problem. We analyzed the results and predictors of in-hospital adverse events in patients undergoing elective percutaneous coronary intervention (PCI) after fibrinolysis. Methods: Three hundred and three patients with diagnosis of AMI undergoing pharmacological reperfusion and transferred to a tertiary center for elective PCI were selected. Results: The population included mostly men (76.6%), with mean age of 59.4 + 11.1 years, 18.1% were diabetic and 86.8% were in Killip class I. Streptokinase was used in 91.7%, the mean time to perform elective PCI was 5.6 + 3.7 days after fibrinolysis and TIMI 3 flow was achieved in 74.2% of the patients. Stents were implanted in 97.7% and angiographic success was obtained in 95.3% of the cases. Mortality was observed in 3.3%, reinfarction in 3.6%, target lesion revascularization in 1.3%, and major bleedings in 2% of the patients. Multivariate analysis indicated female gender, age > 65 years, TIMI 1 flow, thrombus in the treated vessel, Killip > I and severe left ventricular dysfunction were independent predictors of in-hospital adverse events. Conclusions:The pharmacological reperfusion strategy followed by transfer to perform elective PCI had low in-hospital adverse event rates and is an interesting alternative to primary PCI in Brazil. However, public policies are required to improve the logistics to better handle these patients and have them available to all low and medium complexity national hospitals.

The diagnosis of paracoccidioidomycosis requires epidemiological data to be available and for the presence of some more typical clinical manifestations.It requires complementary investigation with interventional methods, differential diagnosis of pathologies of great importance such as tuberculosis and lymphomas, and cure control. This update discusses the advances in these various areas, which include complementary investigation, differential diagnosis and cure control, pointing to development prospects that may help better define the best approach to this disease.

Paracoccidioidomycosis, despite being the most important deep mycosis in Latin America, still has many blindspots in terms of its approach, especially in relation to duration of treatment, cure control and prophylaxis. Depending on severity, the following can be used in the treatment: sulfonamides, azoles (itraconazole and ketoconazole), and amphotericin. The prognosis depends on severity, time between onset and diagnosis, and therapy instituted. In mild forms, prognosis is good; in moderate and severe forms, for which there is risk of developing sequelae and death, it is guarded.